This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PEARL W. YEE, M.D. INC. OF SAN FRANCISCO ANNOUNCES THE AVAILABILITY OF STATE-OF-THE-ART BREAST CANCER RISK ASSESSMENT TEST

SAN FRANCISCO, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pearl Yee, MD, FACOG and clinical professor at the University of California, San Francisco, is pleased to announce that her private practice, Pearl W. Yee, M.D. Inc, in San Francisco is now offering the BREVAGen™ predictive risk test. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer.

BREVAGen Logo
desc

"Personalized medicine and genetic screening have evolved, and we now have the tools to fuel one of my greatest passions, which is preventing cancer. I now expect my patients to live well into their 90s. With proper medical insights using tests like BREVAGen, we can help women understand their personal risk of developing cancers such as breast cancer; better understand their personal risk of using hormone replacement therapies; and, avoid unnecessary testing," said Dr. Yee. "Having pioneered the use of robotic surgery and minimally invasive surgery, I'm passionate about utilizing new technology to improve patient care. BREVAGen helps us understand each patient's risk so we can then develop personalized breast health and monitoring plans tailored to their specific risk and needs. BREVAGen helps me identify women who might need more frequent testing and those who might require less. This will help reduce the incidence of advanced breast cancer cases we see, help save lives and help control medical costs."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs